GLAND PHARMA
|
GLAND PHARMA Last 5 Year Financial Ratios History
[Consolidated]
Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|
Operational & Financial Ratios | ||||
Earnings Per Share (Rs) | 47.42 | 73.75 | 60.94 | 49.88 |
CEPS(Rs) | 56.33 | 80.46 | 66.98 | 55.98 |
DPS(Rs) | - | - | - | - |
Book NAV/Share(Rs) | 483.12 | 434.84 | 359.30 | 234.25 |
Tax Rate(%) | 25.94 | 25.14 | 25.31 | 22.16 |
Margin Ratios | ||||
Core EBITDA Margin(%) | 25.90 | 34.32 | 37.61 | 36.28 |
EBIT Margin(%) | 30.13 | 36.90 | 38.64 | 37.98 |
Pre Tax Margin(%) | 29.92 | 36.78 | 38.55 | 37.71 |
PAT Margin (%) | 22.16 | 27.53 | 28.79 | 29.35 |
Cash Profit Margin (%) | 26.32 | 30.04 | 31.64 | 32.94 |
Performance Ratios | ||||
ROA(%) | 9.40 | 16.91 | 18.84 | 18.91 |
ROE(%) | 10.34 | 18.61 | 20.97 | 21.29 |
ROCE(%) | 14.04 | 24.85 | 28.00 | 27.39 |
Asset Turnover(x) | 0.42 | 0.61 | 0.65 | 0.64 |
Sales/Fixed Asset(x) | 1.61 | 2.51 | 2.49 | 1.95 |
Working Capital/Sales(x) | 0.57 | 0.84 | 0.75 | 1.06 |
Efficiency Ratios | ||||
Fixed Capital/Sales(x) | 0.62 | 0.40 | 0.40 | 0.51 |
Receivable days | 100.77 | 72.40 | 67.08 | 83.41 |
Inventory Days | 162.12 | 102.05 | 107.06 | 104.83 |
Payable days | 113.72 | 74.35 | 96.63 | 108.75 |
Valuation Parameters | ||||
PER(x) | 26.75 | 44.33 | 40.66 | - |
PCE(x) | 22.52 | 40.63 | 36.99 | - |
Price/Book(x) | 2.63 | 7.52 | 6.90 | - |
Yield(%) | - | - | - | - |
EV/Net Sales(x) | 4.86 | 11.50 | 10.84 | -0.50 |
EV/Core EBITDA(x) | 14.85 | 29.19 | 26.12 | -1.19 |
EV/EBIT(x) | 16.13 | 31.18 | 28.05 | -1.30 |
EV/CE(x) | 1.95 | 6.46 | 5.78 | -0.32 |
M Cap / Sales | 5.93 | 12.21 | 11.71 | - |
Growth Ratio | ||||
Net Sales Growth(%) | -19.91 | 27.08 | 31.51 | - |
Core EBITDA Growth(%) | -33.49 | 20.67 | 31.28 | - |
EBIT Growth(%) | -34.60 | 21.34 | 33.82 | - |
PAT Growth(%) | -35.54 | 21.54 | 29.00 | - |
EPS Growth(%) | -35.70 | 21.01 | 22.18 | - |
Financial Stability Ratios | ||||
Total Debt/Equity(x) | - | - | - | - |
Current Ratio(x) | 9.46 | 10.05 | 10.00 | 7.93 |
Quick Ratio(x) | 6.80 | 8.02 | 7.51 | 5.82 |
Interest Cover(x) | 142.61 | 309.77 | 392.33 | 139.24 |
Total Debt/Mcap(x) | - | - | - | - |
Compare Financial Ratios of peers of GLAND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAND PHARMA | ₹28,945.2 Cr | 0.8% | -3.9% | 45.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹356,625.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
CIPLA | ₹112,938.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹101,315.0 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹99,276.9 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹93,921.9 Cr | 5% | 10.4% | 109.1% | Stock Analytics |
GLAND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | 0.8% |
-3.9% |
45.7% |
SENSEX | 1.3% |
2.6% |
24% |
You may also like the below Video Courses